Enlivex Therapeutics (NASDAQ:ENLV) Stock Price Up 6% – Time to Buy?

Posted by Linda Flegge on Jan 4th, 2025

Shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV – Get Free Report) traded up 6% during trading on Thursday . The company traded as high as $1.25 and last traded at $1.24. 94,208 shares changed hands during mid-day trading, a decline of 35% from the average session volume of 145,177 shares. The stock had previously closed at $1.17.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ENLV shares. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Enlivex Therapeutics in a research report on Friday, September 27th. D. Boral Capital restated a “buy” rating and issued a $13.00 price objective on shares of Enlivex Therapeutics in a report on Wednesday, December 11th.

View Our Latest Report on ENLV

Enlivex Therapeutics Trading Up 0.8 %

The company has a market cap of $26.76 million, a P/E ratio of -1.28 and a beta of 1.01. The business has a 50 day moving average price of $1.20 and a 200-day moving average price of $1.33.

Institutional Trading of Enlivex Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ENLV. XTX Topco Ltd bought a new position in shares of Enlivex Therapeutics in the 2nd quarter valued at about $35,000. Sigma Investment Counselors Inc. acquired a new stake in Enlivex Therapeutics in the 3rd quarter valued at about $50,000. Finally, Armistice Capital LLC bought a new position in Enlivex Therapeutics during the second quarter worth about $2,415,000. 1.02% of the stock is owned by institutional investors.

Enlivex Therapeutics Company Profile

(Get Free Report)

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.